Yang Dae Sik, Sung Hwa Jung, Woo Ok Hee, Park Kyong Hwa, Woo Sang Uk, Kim Ae-Ree, Lee Eun Sook, Lee Jae-Bok, Kim Yeul Hong, Kim Jun Suk, Seo Jae Hong
Department of Radiation Oncology, Medical College, Korea University, Seoul, Korea.
Cancer Genet Cytogenet. 2010 Jan 15;196(2):194-7. doi: 10.1016/j.cancergencyto.2009.10.005.
Published studies on the association between the progesterone receptor gene +331 G/A polymorphism and breast cancer risk are inconclusive, and meta-analysis is required to verify the association. Six studies, including a total of 6,849 cases and 6,589 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the AG + AA variant genotype was not associated with a significantly elevated breast cancer risk [odds ratio (OR) = 1.11; 95% confidence interval (95%CI) = 0.99-1.24; P = 0.071]. However, subgroup analysis revealed that the AG + AA variant genotype was associated with an increased risk of breast cancer in American (OR = 1.32; 95%CI = 1.10-1.58; P = 0.003), but not in European or Australian. We could carefully suggest that the progesterone receptor promoter +331 G/A variant polymorphism might increase breast cancer risk, and this effect appeared to be more prominent in Americans than in Europeans and Australians.
关于孕激素受体基因+331 G/A多态性与乳腺癌风险之间关联的已发表研究尚无定论，需要进行荟萃分析来验证这种关联。六项研究，共纳入6849例病例和6589例对照，进行了荟萃分析。当将所有符合条件的受试者汇总进行荟萃分析时，AG + AA变异基因型与乳腺癌风险显著升高无关[比值比（OR）= 1.11；95%置信区间（95%CI）= 0.99 - 1.24；P = 0.071]。然而，亚组分析显示，AG + AA变异基因型与美国人群乳腺癌风险增加相关（OR = 1.32；95%CI = 1.10 - 1.58；P = 0.003），但在欧洲或澳大利亚人群中并非如此。我们可以谨慎地提出，孕激素受体启动子+331 G/A变异多态性可能会增加乳腺癌风险，并且这种效应在美国人群中似乎比在欧洲人和澳大利亚人群中更为显著。
Zotero 插件